mRNA Vaccine and Drug Proof-of-Concept Services

mRNA vaccines and drugs

The mRNA vaccine broke the traditional immune activation mode of inactivated and attenuated vaccines, and innovatively used human cells to produce antigens to activate specific immunity, which was brilliant during the COVID-19 epidemic. The application prospects of mRNA vaccines and drugs are very broad. In addition to being used for preventing infectious diseases, treating tumors and immune diseases, they can also be applied in various biopharmaceutical platform technologies, such as protein supplementation therapy, cell therapy, antibody drugs, gene editing, and so on. In the post COVID-19 era, mRNA vaccines still have the potential for substantial growth.

Preparation of mRNA immune antigen antibody

mRNA has the potential to encode almost all proteins. MRNA vaccine technology can be applied to antigen preparation to solve the difficulties in protein preparation, such as long preparation cycles, complex production processes, and poor flexibility in customized production of traditional protein antigens. MRNA, as a platform technology, has the advantages of simple production process, short production cycle, and high flexibility. It can provide customers with antigen preparation faster and more cost effectively, and conduct rapid target feasibility verification.

Production Cycle
Production Process
Expression System
Flexibility in customized production
Supporting Infrastructure
Infectious Risk
Difficulty or Facility of Production
Production Costs
Protein Antigen
mRNA Antigen
Long
Short
Complex, low referenceability of processes between different proteins
Relatively simple, with high process reference between different mRNA sequences
Multiple expression systems are needed according to the requirements, and the subsequent process is complex
The expression system is simple, with complete post-translational modification functions and the most perfect physiological environment
Due to the complexity of the process and poor flexibility
Based on different sequence processes, it has high reference value and flexibility
Multiple and complex facilities
Less and simpler
Expressing the risk of infection in the host
No risk of infection
Difficulties and complex production processes
Easy, can be produced on a platform
Tall
Low

Hanhai New Enzyme provides one-stop mRNA vaccine&drug development concept validation services to help customers quickly verify the feasibility of drug targets

- Experienced team has successfully delivered multiple concept validation projects

- Diversified tools are used to predict the secondary structure of proteins using alphafold, providing guidance for customers' antigen design and mRNA sequence design.

- Our independently established mRNA technology and application platform, comprehensive quality system, and full process services from sequence design, mRNA LNP preparation to in vivo biological evaluation.

01
Submit Requirements
02
Sale Confirmation
03
Sequence Design
04
Gene synthesis and plasmid amplification
05
IVT synthesis of mRNA
06
Cell translation level detection
07
08
LNP Encapsulation
Animal in vivo validation
DELIVERY STANDARDS
Service category
Duration (working days)
Deliver
Sequence design
5
10 candidate sequences
Plasmid construction and amplification
30
Plasmids and sequence files, providing synthesized raw plasmids (1-2 μ g)
mRNA raw material synthesis
5
mRNA Raw Liquid Detection Report
mRNA cell translation level detection
10
Translation Proficiency Test Report
LNP encapsulation
10
1mg LNP
In vivo translation level detection (optional)
20
Test report
In vivo cellular immune testing (optional)
10
Test report
Fluid immune testing (optional)
20
Test report
In vivo translation level+humoral immune testing (optional)
20
Test report
In vivo translation level+humoral immune detection+cellular immune detection (optional)
20
Test report
CASE
mRNA vaccine design
01.
Sequence design
02.
Plasmid prep
03.
In vitro transcription synthesis of mRNA
04.
Translation proficiency testing
05.
LNP encapsulation
step1: Confirm amino acid sequence
Based on the AI intelligent tool - Alphafold protein structure prediction and analysis tool, and in cooperation with the State Key Laboratory of Microbiology of Shanghai Jiaotong University, a protein structure prediction and optimization system was built
step2: Decoding DNA nucleotide sequences
Hanhai New Enzyme utilizes various sequence optimization tools to output nucleotide sequence files, providing support for the next optimization step
01
·Target determination: Identify the targets for drug development.
02
·Optimization design: Based on MFE and CAI multi parameter combination, output multiple candidate sequences and sort them.
03
·Screening scheme: Based on the MFE and CAI of the selected sequence, with the standard of covering all sequence sets as comprehensively as possible, select candidate sequences and use them for wet experiments
04
·Experimental verification: Through wet experiments, select the best sequence.
05
·Delivery of optimal sequence: The sequence delivered to the customer will be rigorously screened and most likely to become the optimal candidate for drug phenology.
Step 3: mRNA sequence optimization
① Kozak sequence significantly increases protein expression
— Kozak
+ Kozak
③ Transcription initiation sequence
 
T7 promoter+transcription start sequence   
IVT production  
saRNA-EGFP(AU,UTP)
TAATACGACTCACTATAATG
GGCGGCGCAT
Normal,1:181
TAATACGACTCACTATAATG   CGGCGCAT
No output
TAATACGACTCACTATAAT   CGGCGCAT
No output
④ Verification of A-tail sequence of mRNA.
step4: Software predicts the secondary structure of candidate sequences
Predict the secondary structure of candidate sequences to avoid sequences with stable or hyperstable complementary structures at the 5 'level.
EGFP mRNA
MFE:-314.62
saRNA-EGFP
MFE -2718.90
Step 1: Sequence Design
② UTR adaptability affects the expression effect of CDS sequences
Step 2: Plasmid preparation
1. Strain screening - controlling yield and super helix ratio
monoclonal
competence
2. Fermentation process - control OD600 and plasmid yield
Optimize various parameters for different receptive states and plasmids:
· Cultivation medium formula · Fermentation tank parameters · Feeding formula and feeding strategy · Fermentation tank control parameters
3. Important indicator for plasmid optimization - PolyA tail stability
Different receptive state transformation plasmids, selecting monoclonal antibodies with stable A tail
After fermentation amplification of different plasmid skeletons, the heterozygosity of PolyA tail in sequencing quality inspection varies
By screening the receptive/monoclonal/plasmid backbone and optimizing the fermentation process, we ultimately obtained plasmids with high helix ratios and stable PolyA tails
4. Purification process
(1) Optimization of Cracking Process
(2) Molecular sieve chromatography to remove RNA
(3) Affinity chromatography to remove open-loop plasmids
(4) Ion exchange chromatography to remove endotoxins
5. Product release testing

Quality control items

Number

Testing items

Test method

Bacterial seed bank inspection

1

Bacterial morphology

Microscopic observation

2

Plasmid restriction enzyme digestion map

Restriction endonuclease digestion

3

Target gene sequencing

Sequence

4

Sequencing of other components

Sequence

5

Bacterial identification

Cultivation method/bacterial staining/biochemical reaction

6

Antibiotics resistance

Cultivation method

菌种传代稳定性

1

Plasmid sequence size

Electrophoresis/Sequencing

2

Accuracy of plasmid sequence

Sequence

3

Plasmid restriction enzyme digestion map

Restriction endonuclease digestion

4

Plasmid copy number

ddPCR

5

Passage restrictions

Cultivation method

Quality control of supercoiled plasmids

1

Appearance

Visual inspection method

2

PH value

PH count

3

Purity (A260/A280)

Ultraviolet spectrophotometer

4

Identification of restriction endonucleases

Agarose gel

5

Sequencing identification

Sequence

6

Concentration

Spectrophotometry

7

DNA homogeneity

Electrophoresis or HPLC

8

Host protein DNA residue

Elisa

9

RNA residue

Electrophoretic method

10

Host DNA residue

QPCR

11

Microbial limit/sterility

Membrane Filtration

12

Endotoxin

TAL

WT-T7 (Customer System)

Yield: 191.9 μ g/20 μ L reaction

Integrity: 75.6%

Replace M6/optimize enzyme dosage

Yield: 176.8 μ g/20 μ L reaction

Integrity: 83.0%

Database analysis and buffer optimization

Yield: 240.1 μ g/20 μ L reaction

Integrity: 84.7%

Use enhancers (final IVT system)

Yield: 203.8 μ g/20 μ L reaction

Integrity: 88.2%

After final optimization, meet customer expectations
Step 3: In vitro transcription

Product release testing

Quality inspection items
Quality inspection method
Results Display
Concentration
Nanodrop method
Ribogreen
Integrity
CE
SEC-HPLC
DNA template residue
qPCR
Cap rat
LC-MS
Tail added distribution
LC-MS
Total protein residue
Nanoorange
Product related impurities - NTP residue
SEC-HPLC
Product related impurities - polymer quantification
SEC-HPLC
Product related impurities - residual T7 RNA polymerase content
ELISA
Endotoxin
Recombinant factor C/horseshoe crab reagent
Step 4: Translation proficiency testing
Verification level
Test method
Cycle
Results Display

Verification of intracellular expression levels

Fluorescence microscopy detection
3 days
Flow analysis

3 days

Detection of firefly luciferase
3 days

Immunofluorescence IF

3 days
WB
3 days
ELISA
3 days
In vivo expression level validation

In vivo imaging

1-2 days

Serum protein expression detection

2 days

Step 5: LNP encapsulation
LNP microfluidic control preparation process
Prepare ethanolic lipid mixture with cationic lipid,phospholipid, sterol lipid,and PEGylated lipid
Prepare aqueous oligonucleotide solution
Mix using a range of specialized-to-basic equipment methods
Optional: Perform size extrusion
Uniformly sized lipid nanoparticles
Hanhai New Enzyme has explored and optimized the downstream purification process for LNP, mainly focusing on the development of inlet flow rate, Trans Membrane Pressure Drop (TMP), membrane pore size, membrane area, membrane material, hollow fibers, and flat plate membrane package. The process time can be controlled at around 3.5 hours, and the stability of mRNA LNP preparation at -80 ℃ can reach more than 18 months, and it can be frozen and thawed 10 times without affecting physical and chemical indicators
Long term stability of mRNA LNP preparation at -80 ℃
Freeze thaw stability of mRNA LNP formulations

Product release testing 

Quality inspection items
Quality inspection method
Results Display
Entrapment efficiency
Ribogreen
Preparation RNA concentration
PDI/particle size
DLS
Zeta potentials
Doppler electrophoresis
Molecular molar ratio of multivalent RNA molecules
ddPCR+qPCR
RNA sequence confirmation
Sanger sequencing/RT-PCR
Determination of lipid content
ELSD-HPLC
RNA integrity
CE/HPLC
Endotoxin
Recombinant factor C/horseshoe crab reagent
Protein expression validation
WB/FACS/IF/ELISA



Service ordering and consultation
Website Link
Learn more
© 2023 Hzymes Biotechnology Co., Ltd All rights reserved
Contact Us
Tel:400-808-5320
Email:hhxm-info@hzymes.com
Large scale production base: Building 6, Wuhan Precision Medical Industry Base, No. 9 Gaokeyuan Third Road, Wuhan City
Global Marketing Center: Hanhai Building, No. 3006 Huancheng West Road, Fengxian District, Shanghai
Customer service
Powered by Feedback Manage